Shares of ArQule (ARQL +2.4%) move up after the company says it's enrolled the first patient in...
Shares of ArQule (ARQL +2.4%) move up after the company says it's enrolled the first patient in its Phase 3 trial of tivantinib, which is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma who have received one or two prior systemic anti-cancer therapies. The company expects to enroll about 300 patients at approximately 120 clinical centers worldwide.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs